While the interaction between ABHD5 and PNPLA3 describes a potential mechanism by which the I148M variant causes MASLD, a better understanding of the biochemical basis of the interaction is required to develop novel therapeutics. Here, ABHD5 is linked to metabolic dysfunction-associated steatotic liver disease.